adhdresearch.news
← Latest research
Paper published Added
PubMed

Genetic Tests Can't Tell You Which ADHD Medication Will Work Best for Your Child

A review of genetic testing for children's mental health medication says these tests may help flag side-effect risk in some children. They can't predict which medication will work best for a particular child. The authors also warn that some commercial reports use simple color-coding that can mislead both families and doctors.

What you can do

If you're considering a genetic test for a child's ADHD medication, treat it as a possible tool for anticipating side-effect risk, not for choosing the most effective drug, and go over any color-coded report with a clinician who understands its limits.

Evidence
Study design
narrative review
Population
Children and adolescents with depression, anxiety, or ADHD (pediatric populations; no specific sample described)
Sample size
Abstract-only; no sample size reported. Appears to be a narrative/expository review, so this is not a primary-data study.
Intervention / exposure
Pharmacogenomic testing to inform psychotropic medication selection (no dose or duration specified)
Comparator
Not reported
Key results
  • Utility of pharmacogenomic testing for identifying psychotropic medication tolerability or adverse effects: Authors state testing 'can be useful in certain populations to identify a psychotropic medication's tolerability or adverse effects.' No quantitative data in abstract.
  • Ability of pharmacogenomic testing to predict clinical response: Authors state testing 'cannot predict which medication will provide the best clinical response in a specific patient with a specific mental illness.'
Limitations
  • Abstract-only extraction; no methods, search strategy, or data are available, so the design is inferred as narrative review from the content.
  • Authors note testing 'require[s] nuanced understanding and interpretation' in pediatric depression, anxiety, and ADHD.
  • Authors state testing cannot predict which medication will give the best clinical response.
  • Authors caution that some commercial kits give clinical guidance based on genetic tests that 'may not have clinical relevance' in an 'over-simplified color-coded format which can be misleading for the patient and for the clinician.'
  • Usefulness is described as limited to 'certain populations' for tolerability/adverse effects; the populations are not specified in the abstract.
Source reviewed
Abstract
References

Rahmani M. Utility of pharmacogenomic tests in treating pediatric depression, anxiety and ADHD. Current problems in pediatric and adolescent health care. 2026-10-16